Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab

Lize Wang(Peking University), Tao Ouyang(Peking University), Yang Zhang(Dalian Medical University), Jinfeng Li(Hebei Medical University), Zhaoqing Fan(Daqing Oilfield General Hospital), Yuntao Xie(Peking University), Tianfeng Wang(Peking University), Yingjian He(Peking University)
npj Breast Cancer
June 11, 2021
Cited by 5


Related Papers